NCT03978624 2025-10-15
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT04383743 2025-09-18
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
Phase 2 Completed
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT00777491 2022-06-15
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00055601 2018-06-15
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00380029 2017-07-19
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00859339 2016-04-14
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
Hoosier Cancer Research Network
Phase 2 Terminated
NCT01916109 2016-02-12
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00585689 2015-11-30
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed